Cardiotoxicity from immune checkpoint inhibitors

Immune checkpoint inhibitor (ICI) therapy has greatly improved treatment of various advanced cancers but increasing use of ICI therapy has exposed the risk of ICI-related cardiovascular side effects. Immune checkpoints are inhibitory regulators of T cell activation and mediate T cell effector functi...

Descripción completa

Detalles Bibliográficos
Autores principales: Michel, Lars, Rassaf, Tienush, Totzeck, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736791/
https://www.ncbi.nlm.nih.gov/pubmed/31517036
http://dx.doi.org/10.1016/j.ijcha.2019.100420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736791/
https://www.ncbi.nlm.nih.gov/pubmed/31517036
http://dx.doi.org/10.1016/j.ijcha.2019.100420

Ejemplares similares